ClinicalTrials.gg
CompletedNCT00377624Updated Jan 11, 2011

HUPS: Hyalgan Use in Painful Shoulder

A Phase 3 interventional study of sodium hyaluronate in Osteoarthritis of Shoulder, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2011-01-11.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
602
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing Hyaluronic Acid in Osteoarthritis — 2 open to participants now, 2 under way, none of them phase 3. Hyaluronic Acid · Osteoarthritis.

Enrollment
Largest of 15
602 · median 60
Started
2002
the only one that year
Phase 3
2 of 16
none open now
Registered
3rd of 16
by date
Lead sponsor
3 of 16
Sanofi

Among the 16 studies testing Hyaluronic Acid in Osteoarthritis, this one has the largest enrollment of the 15 interventional ones that give a count, is the only one that started in 2002, is one of 2 in phase 3, and was the 3rd registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

2 of the 16 studies testing Hyaluronic Acid in Osteoarthritis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Hyaluronic Acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing Hyaluronic Acid in Osteoarthritis, or all of them as a file.
02

Study summary

Three-arm, parallel, double-blind, masked observer, randomized, PB-Saline controlled clinical trial. In order to avoid problems in the interpretation of the final results due to disparate enrollment from various centers, the number of patients enrolled per site will be the same per site. Study patients will be randomized to receive either 20 mg sodium hyaluronate, 3 i.a. sodium hyaluronate injections, followed by 2 PBSaline mock i.a. injections or 5 i.a. PB-Saline control injections. One investigator will administer the injection and the joint assessor will be blinded to the study. The anterior or posterior approach for the shoulder injection will be used.

03

Conditions studied

  • Osteoarthritis of Shoulder

Browse trials for

04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.

Inclusion criteria

INCLUSION CRITERIA:

  1. Patients with chronic shoulder pain with all of the following: of at least 6 months, but not greater than 5 years duration without improvement in shoulder pain over the past one month, and present at least 50% of the days during the previous month.
  2. Patients who have failed conventional therapy including but not limited to the following: NSAIDs; one or more i.a. or local peri-articular injections and physiotherapy (a minimum of one month of previous physiotherapy treatment is required.
  3. At screening, patients on chronic analgesic/anti-inflammatory medication should have a VAS pain score of >/= 30 mm and \</= 90 mm indicating a lack of adequate and sustained response to previous and current therapies. At screening, patients not on chronic analgesic/anti-inflammatory medication should have a VAS pain score of >/= 40 mm and \</= 90 mm. If bilateral shoulder pain is present, the investigator will use the more painful shoulder.
  4. At baseline, after all analgesic/anti-inflammatory medications have been discontinued for 2 weeks, patients should have a VAS pain score of >/= 40 mm and \</= 90 mm.
  5. Patients with a limitation of shoulder motion in at least 1 direction at screening and baseline for the following active range of motions: Abduction with scapula fixed must be \</= 80°; internal rotation in abduction must be ,/= 55°, and/or external rotation in abduction must be 180°. These limitations of shoulder motion are in comparison to normal expected ranges.
  6. Patients with a retained active Range Of Motion ("ROM") >/= 30 percent in all directions at screening and baseline to rule out frozen shoulder. The ROM should be: >/= 30° for abduction with scapula fixed, >/= 30° external rotation, and >/= 20° for internal rotation.
  7. Patients with at least one of the following conditions as examined and determined by Investigator: Osteoarthritis of the Glenohumeral Joint (OA), Rotator cuff tear (complete or partial), Adhesive capsulitis of the shoulder.
  8. Patients who are able to complete efficacy measurement questionnaires.
  9. Patients who are willing to discontinue all NSAIDs or other analgesic medication taken for their shoulder pain at least 2 weeks prior to baseline evaluation, with the exception of acetaminophen 500-1000 mg (1-2 tablets) q.i.d., p.r.n. (maximum 8 tablets or 4 grams per day) which would be sole rescue medication. Acetaminophen must not be taken within 24 hours of any visits or valuations. Patients must also be willing to abstain from any i.a. or peri-articular injections for the shoulder during the course of the trial, except for the assigned study product.

Exclusion criteria

EXCLUSION CRITERIA

A. GENERAL MEDICAL CONDITIONS

  1. Women of may not be entered if pregnant, nursing, or not using effective method of until all follow-up procedures are complete.
  2. Participation in an experimental drug/device study within the previous 30 days.
  3. Prior history of any , with the exception of basal cell carcinoma of the skin treated more than 2 years ago, unless specific permission of the Sponsor is granted.
  4. Significant bleeding diathesis.
  5. Active liver disease, conjugated , renal insufficiency, abnormal blood counts, or any laboratory value, which the investigator feels, may affect the evaluation of the patient.

B. MUSCULOSKELETAL RELATED

  1. Major injury including sports related injury to the shoulder within the past year.
  2. Patients with chronic shoulder pain more than 5 years duration.
  3. Any cervical spine disease that could confound the clinical assessment; chronic acromioclavicular disease, thoracic outlet syndrome, active epicondylitis, or symptomatic carpal tunnel disease, any musculoskeletal disease that could confound the diagnosis/evaluation of the painful shoulder, or any neurological etiology of the pain and any acute infection of the joint.
  4. Surgery to the study joint within the previous 12 months.
  5. Inflammatory arthropathy such as rheumatoid arthritis, lupus, psoriatic arthritis or Milwaukee shoulder.
  6. Frozen shoulder involving either shoulder.
  7. Patients with clinically significant shoulder pain improvement in the past month.
  8. Gout or calcium pyrophosphate diseases involving the upper extremity that has flared within the previous 12 months.
  9. Intra-articular or local peri-articular injections to the study joint or shoulder within the previous 3 months; or to any other joint within the previous month; or any oral corticosteroid within the previous month. Steroid inhalants are permitted if the patient has been on a stable regimen for the past month and remains on this regimen throughout the course of the trial. Low dose aspirin (325 mg or less) as an anti-thrombotic treatment is permitted if stable for one month prior to Screening and stable throughout the trial.
  10. Patients who never received i.a. or peri-articular corticosteroid therapy for the signal shoulder. This includes patients with (s) to corticosteroids.
  11. Intra-articular hyaluronan in the study joint within the previous 12 months. Use of glucosamine-or chondroitin sulfate-containing products unless at Screening the patient is on stable doses for at least 4 months and willing to remain on these stable doses throughout the course of the trial. Use of bisphosphonates unless at Screening the patient is on stable doses for the past month and willing to remain on these stable doses throughout the course of the trial.
  12. Patients with shoulder X-ray findings of acute fractures, severe loss of bone density, a vascular necrosis and/or severe deformity.
  13. Patients with documented evidence of clinically significant shoulder joint deformities.
  14. If patients are receiving or performing physical therapy at screening, this physical therapy regimen must have been stable during the one-month preceding screening and remain stable throughout the course of the trial.
  15. Patients with primary extra-articular shoulder syndromes in the absence of intra-articular disease such as uncomplicated impingement syndrome without limitation in ROM, bursitis and tendinitis without evidence of adhesive capsulitis.
  16. Patients with Kellgren-Lawrence Stage IV osteoarthritis of the glenohumeral joint.
  17. Any arthrogram of the signal joint within the past 3 months.

C. CONCOMITANT CONDITIONS, DISEASES, MEDICATIONS AND/OR CLINICAL HISTORY.

  1. Patients with known allergies to acetaminophen, lidocaine, hyaluronan, or avian products.
  2. Patients requiring chronic analgesia for any other condition (including chronic pain in the contralateral shoulder or another joint) that may interfere with the evaluations of the signal shoulder.
  3. Patients with a recurrent medical history of severe allergic or immune-mediated reactions.
  4. Patients with active infection of the skin in the vicinity of the potential injection site.
  5. Patients taking any agent reported to have symptom relief for arthritis or be a disease/structure modifying drug.
  6. Patients on concomitant therapy with anticoagulants.
  7. Patients with any inter-current disease(s) or condition(s) that may interfere with the free use and evaluation of the affected shoulder for the 6-month course of the trial.
  8. Patients with any inter-current chronic disease(s) or condition(s) that may predispose them to a high probability of interfering with the completion of the 6 month follow-up of the study such as peptic ulcer, liver disease, severe coronary disease, renal disease, cancer, pregnancy, alcoholism, drug abuse, mental state, or other clinically significant condition.
  9. Patients participating in any clinical trial within one month of trial entry.
  10. In the opinion of the clinical investigator a clinically significant abnormal laboratory test result(s) that may place the patient at a health risk, impact upon the study, or the patient's ability to complete the study.
  11. Patients unable to legally comprehend the details and nature of the study.
  12. Patients who - in the judgment of the clinician - are likely to violate the protocol regulations or unlikely to complete the study for any reason.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
602 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Improvement in shoulder pain on movement in previous 24 hours, based upon 100 mm VAS score up to 3 months after baseline for the 3 i.a. and 5 i.a. sodium hyaluronate injections compared to PB-Saline control

Secondary outcomes

  1. Maintenance or improvement from baseline in shoulder pain on movement in previous 24 hours based upon 100 mm VAS score up to 6 months after baseline of

  2. sodium hyaluronate treated patients compared to PB-Saline.

07

Study locations

1 site
  • Sanofi-Aventis
    Bridgewater, New Jersey 08807, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2002 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2006
First posted
Sep 18, 2006
Start
Jan 2002
Completion
Sep 2004
Last update
Jan 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jan 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00377624
Lead sponsor
Sanofi
First posted
Sep 18, 2006
Start date
Jan 2002
Completion
Sep 2004
Last update
Jan 11, 2011

Study contacts

Phyllis Diener, MT, ASCP
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion